PSQH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PSQH is not a good buy right now for an impatient investor. The chart is in a clear downtrend (bearish moving-average stack and worsening MACD), and the latest catalyst (direct offering + CEO change) is dilution/financial-stress coded. Despite being extremely oversold (RSI~19) and capable of a sharp dead-cat bounce, there is no Intellectia buy signal to prioritize, and the risk/reward is unfavorable versus waiting for trend stabilization above key levels (at least reclaiming S1/Pivot).
Trend is bearish. SMA_200 > SMA_20 > SMA_5 confirms persistent downside momentum. MACD histogram is negative (-0.00569) and expanding lower, signaling bearish momentum is strengthening rather than bottoming. RSI_6 at 18.892 is deeply oversold, which can trigger short-term bounces, but oversold alone is not a buy signal when trend/momentum keep deteriorating.
Key levels: Current price ~0.8276 is below S1 (0.868) and below Pivot (1.056), indicating price is trading in a weak zone. Next downside support is S2 ~0.752; a break below that would likely extend the selloff. Upside resistance is S1 (0.868) then Pivot (1.056); a reclaim of these would be the first sign of stabilization.
Intellectia Proprietary Trading Signals
can produce a sharp short-term rebound if selling pressure exhausts.
A $7.5M direct offering and the stock’s >20% drop on the announcement are strong dilution/financing-risk signals and can cap near-term upside.
CEO resignation and abrupt leadership change increase uncertainty during an already weak price trend.
Bearish trend structure (moving averages + MACD worsening) indicates the selloff is not yet technically “done.”
Trading trends show no supportive accumulation: hedge funds neutral and insiders neutral (no strong confidence signal).
Latest reported quarter: 2025/Q3. Revenue rose to 4,404,861 (+37.33% YoY), but profitability worsened: net income was -11,982,888 (more negative YoY), EPS -0.26 (down 36.59% YoY), and gross margin fell to 28.48 (down 61.51% YoY). Net losses and sharply weaker margin alongside a dilutive raise point to stressed unit economics/cash needs despite top-line growth.
No analyst rating trend or price target change data was provided. From a ‘Wall Street pros/cons’ lens based on available info: Pros—revenue growth and a CEO with fintech focus could improve strategic execution. Cons—material losses, collapsing gross margin, and dilution risk dominate the near-term narrative, which typically keeps institutional/analyst enthusiasm muted until fundamentals stabilize.
